Connected Drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Standalone Components & Software, Integrated Devices), By Route of Administration (Parenteral, Inhalational), By Application (Asthma, COPD, Diabetes Management, Others), By Region & Competition, 2020-2030F

Market Overview

Global Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.25%. The Global Connected Drug Delivery Devices Market is undergoing a significant evolution, shaped by the integration of advanced digital technologies, shifting healthcare delivery models, and the rising emphasis on personalized, outcomes-driven care. These next-generation drug delivery systems equipped with embedded sensors, Bluetooth connectivity, companion mobile apps, and cloud-based analytics are purpose-built to enhance medication adherence, deliver actionable health insights, and improve long-term treatment outcomes, particularly for chronic disease management.

Positioned at the nexus of healthcare innovation, digital transformation, and pharmaceutical advancement, this market is gaining strong momentum. Stakeholders across the ecosystem including biopharma companies, medtech firms, payers, and providers are actively investing in connected therapeutic platforms that support remote monitoring, automate adherence tracking, and enable real-time patient engagement. As regulatory frameworks mature and digital health reimbursement becomes more structured, the market is set to scale rapidly, especially in regions with growing chronic disease burdens and increasing digital infrastructure. The connected drug delivery landscape is no longer a niche it's emerging as a strategic pillar in the future of precision medicine and decentralized care delivery.

Key Market Drivers

Rising Prevalence of Chronic Diseases Requiring Long-Term Medication

The escalating global burden of chronic diseases is a primary catalyst fueling the growth of the Global Connected Drug Delivery Devices Market. Chronic diseases such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses now represent the primary drivers of mortality and long-term disability worldwide. These conditions account for approximately 75% of all global deaths, underscoring their disproportionate impact on both public health and economic productivity. Chronic diseases account for nearly three-quarters of global deaths and continue to rise due to aging populations, sedentary lifestyles, urbanization, and poor dietary habits.

Over 537 million adults are currently living with diabetes, a number expected to exceed 783 million by 2045. According to the Global Initiative for Asthma (GINA), asthma remains one of the most widespread chronic non-communicable diseases, impacting more than 260 million individuals globally. It is a major contributor to global morbidity and is linked to over 450,000 deaths annually. The high incidence and mortality associated with asthma reflect a persistent gap in disease control, adherence, and access to effective management tools particularly in underserved regions. This highlights a growing market opportunity for connected respiratory drug delivery solutions that can improve treatment precision, monitor patient adherence in real time, and reduce preventable asthma-related complications. These diseases often require daily or weekly medication regimens involving injectables, inhalers, or complex drug delivery protocols. This rapidly growing patient pool directly increases demand for connected devices that ensure accurate dosing, adherence tracking, and ongoing patient support.

Medication non-adherence is a major concern in chronic disease management, leading to worsening health outcomes, increased hospitalizations, and higher healthcare costs. Research consistently indicates that 40% to 60% of patients managing chronic conditions exhibit poor medication adherence, frequently skipping doses, mismanaging dosage schedules, or discontinuing treatment prematurely. Connected drug delivery devices help solve this challenge by: Providing automated reminders and alerts through mobile apps. Tracking real-time usage and sending adherence data to healthcare providers. Enabling patient engagement through visual feedback, usage history, and digital coaching. By improving adherence, these devices not only enhance clinical outcomes but also align with the priorities of healthcare payers and providers who are focused on value-based care delivery. Patients with chronic conditions often require long-term, consistent drug administration that can be managed at home without the need for frequent clinic visits. Connected drug delivery devices support this transition by enabling: Self-injection or inhalation with minimal training, even for biologics and specialty medications. Real-time feedback to ensure correct usage, minimizing the risk of administration errors. Remote data sharing with physicians, allowing for continuous therapy optimization and proactive intervention. This functionality is especially crucial for diseases like rheumatoid arthritis, multiple sclerosis, and hormone disorders, where biologics and specialty injectables are becoming the standard of care.

Advancements in Digital Health Technologies and IoT Integration

The rapid evolution of digital health technologies particularly the integration of Internet of Things (IoT), mobile platforms, cloud connectivity, and data analytics is playing a pivotal role in accelerating the growth of the Global Connected Drug Delivery Devices Market. These innovations are transforming conventional drug delivery systems into smart, connected therapeutic tools that offer real-time data tracking, enhanced adherence, and patient-specific insights, aligning with modern healthcare’s shift toward personalized, preventive, and decentralized care. Digital health technologies allow connected drug delivery devices to track and transmit real-time information related to drug administration, including dose timing, frequency, and technique. IoT-enabled devices, such as smart inhalers, insulin pens, autoinjectors, and wearable injectors, can instantly log each administration event and sync it with mobile apps or cloud platforms. These systems provide automated reminders, alerts, and push notifications, helping patients stay compliant with prescribed regimens. Physicians and caregivers can remotely access adherence data, enabling proactive intervention before complications arise. This functionality is particularly valuable in managing chronic diseases like diabetes, asthma, and rheumatoid arthritis, where poor adherence directly affects outcomes and cost of care.

IoT integration allows for seamless data collection across multiple endpoints, including connected drug delivery devices, wearables (e.g., glucose monitors, smartwatches), and health apps. These devices are central to building patient-centric care ecosystems that promote engagement and self-management. Patients receive real-time feedback on their adherence patterns and therapeutic progress, boosting confidence and autonomy. Data analytics platforms can generate personalized dashboards, coaching content, and medication insights tailored to individual behaviors and outcomes. Integration with electronic health records (EHRs) and digital therapeutics platforms enables continuous, closed-loop communication between patients and care teams. This shift from episodic to continuous care improves disease control, reduces hospitalization, and supports the broader goals of outcome-based healthcare.

The expansion of telehealth and decentralized healthcare models has created a strong need for connected self-administered drug delivery solutions. IoT-enabled devices address this need by facilitating: Remote monitoring of patients outside hospital settings, reducing the strain on healthcare infrastructure. Real-world data generation that supports clinical decision-making and therapy adjustments without the need for in-person visits. Seamless participation in decentralized clinical trials, where drug usage data is automatically captured and transmitted to researchers. These capabilities are especially relevant in the post-COVID era, where remote care delivery and virtual trials have become standard practice in many regions.

Download Free Sample Report

Key Market Challenges

High Cost of Devices and Limited Reimbursement Support

One of the most significant barriers to market expansion is the high upfront cost associated with connected drug delivery devices, especially compared to traditional drug administration methods. These devices often incorporate advanced features such as Bluetooth connectivity, integrated sensors, and cloud-based data transmission all of which increase production costs.

For healthcare providers and payers, especially in price-sensitive markets, justifying the added cost becomes challenging without a clear and quantifiable return on investment (ROI). Reimbursement frameworks remain fragmented and inconsistent across regions. In many countries, connected devices are not fully covered under public or private insurance plans, limiting patient accessibility particularly in low- and middle-income economies. Additionally, the cost of accompanying digital infrastructure (such as mobile apps, cloud platforms, and device integration with EHRs) can further complicate adoption. Until reimbursement models evolve to recognize the long-term cost savings of improved adherence and reduced hospitalizations, affordability will continue to be a limiting factor.

Data Privacy, Cybersecurity, and Regulatory Uncertainty

As connected drug delivery devices generate, store, and transmit sensitive patient health data, data privacy and cybersecurity concerns have become a critical challenge.

These devices are often part of larger digital health ecosystems, making them vulnerable to hacking, unauthorized access, or data breaches, especially when encryption and security protocols are not robust. Compliance with regional data protection regulations (such as HIPAA in the U.S. and GDPR in the EU) adds further complexity, as device manufacturers must navigate a patchwork of legal requirements across different jurisdictions. Regulatory agencies are still evolving their guidelines around connected health devices, creating uncertainty regarding approvals, device classification, and post-market surveillance requirements. This lack of regulatory standardization slows down product development cycles and discourages smaller or mid-sized companies from entering the market due to compliance risks and operational costs.

Key Market Trends

Integration of Artificial Intelligence (AI) and Advanced Analytics into Connected Devices

One of the most significant trends shaping the future of connected drug delivery devices is the integration of AI and real-time analytics. Modern devices are evolving from passive tracking tools into intelligent therapeutic systems capable of learning from user data and dynamically optimizing treatment regimens.

Predictive dosing algorithms can now analyze historical adherence data, biometrics (e.g., blood glucose levels), and behavioral trends to fine-tune dosage recommendations in real time. AI-driven insights allow early identification of non-compliance, adverse events, or therapy deviations, which helps healthcare providers intervene proactively. This trend is particularly impactful in chronic disease management such as diabetes and asthma, where continuous optimization of therapy enhances patient outcomes while reducing hospitalization costs. Pharmaceutical companies are increasingly partnering with digital health firms to develop smart therapeutics, combining connected devices with data-driven platforms, creating a seamless patient-provider feedback loop.

Rise of Home-Based Care and Patient-Centric Drug Delivery Models

Healthcare systems across the globe are shifting toward decentralized, home-based care models, accelerated by the COVID-19 pandemic and the growing demand for patient autonomy. Connected drug delivery devices are at the center of this transformation.

These devices enable self-administration of complex therapies (e.g., biologics, insulin, hormone injections) without clinical supervision. With features like automated dose reminders, mobile app integrations, and cloud-based monitoring, patients can manage treatments with greater confidence and independence. For healthcare providers, these devices offer remote access to real-time adherence and dosing data, facilitating virtual consultations and timely interventions. As payers and governments aim to reduce the cost burden of frequent hospital visits, this trend is creating a significant demand spike for connected devices that can support high-acuity care in low-resource or home settings.

Segmental Insights

Route of Administration Insights

Based on the category of Route of Administration, the Parenteral segment emerged as the fastest growing in the market for Connected Drug Delivery Devices in 2024. The growing pipeline and commercialization of biologics and specialty drugs especially for chronic and complex conditions such as diabetes, cancer, rheumatoid arthritis, and multiple sclerosis has significantly boosted the use of parenteral drug delivery. These therapies often require precise dosing, frequent administration, and tight adherence schedules. Connected parenteral devices, such as smart autoinjectors and wearable injectors, meet these needs by integrating dose tracking, patient reminders, and real-time data transmission to caregivers and healthcare providers.

Innovations in connected autoinjectors, pen injectors, and wearable drug delivery systems have transformed the user experience for parenteral administration. These devices come equipped with Bluetooth or NFC capabilities, enabling them to sync with mobile apps and electronic health records (EHRs). They not only monitor adherence but also alert users about missed doses, provide injection guidance, and even adjust dosing regimens using AI-powered algorithms. These features significantly increase user convenience, which drives faster adoption, especially for home-based care. There is a growing global trend toward decentralized healthcare, where patients prefer self-administration of injectable therapies in the comfort of their homes rather than in clinical settings. Connected parenteral devices support this shift by providing patient support through digital interfaces, remote monitoring by healthcare providers, and improved safety through error-reduction mechanisms. This convenience is particularly critical for patients undergoing long-term therapies. These factors contribute to the growth of this segment.

Application Insights

Based on the category of Application, the Diabetes Management segment emerged as the dominating segment in the market for Connected Drug Delivery Devices in 2024. Diabetes particularly Type 1, and insulin-dependent Type 2 requires lifelong monitoring and medication adherence, making it a prime candidate for connected drug delivery solutions. As of the latest estimates, approximately 537 million individuals globally are living with diabetes, with more than 80% residing in low- and middle-income countries a distribution that highlights significant disparities in access to effective disease management. More critically, the burden is expected to intensify sharply, with projections indicating that the global diabetic population will surpass 783 million by 2045. This surge not only signals escalating healthcare costs and infrastructure strain, particularly in emerging markets, but also presents a substantial growth opportunity for connected drug delivery device manufacturers targeting underserved regions with scalable, cost-effective, and digitally enabled insulin management solutions, making diabetes management the largest application area in the market.

Diabetes management heavily relies on injectable insulin therapies, which are ideal for integration with connected drug delivery platforms. Smart insulin pens, connected autoinjectors, and insulin patch pumps enable patients to track dosage history, receive automated reminders, and share glucose and insulin data with healthcare providers in real time. These features significantly enhance medication adherence, reduce errors, and provide valuable insights for personalized treatment adjustments.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the Global Connected Drug Delivery Devices market in 2024, holding the largest market share in terms of value. North America particularly the United States boasts a highly developed healthcare infrastructure that is quick to adopt and integrate emerging digital health technologies. This region has been at the forefront of leveraging digital tools such as IoT, AI, and real-time data monitoring to improve patient outcomes and adherence to therapies. Connected drug delivery devices, which link medication administration with data capture and remote monitoring, align perfectly with this innovation-driven environment.

The growing burden of chronic diseases such as diabetes, asthma, COPD, and cardiovascular conditions significantly contributes to market demand in North America. These conditions often require long-term medication regimens, where connected drug delivery devices help ensure proper dosage, adherence, and timely interventions. Payers and providers are increasingly favoring such technologies to improve clinical outcomes and reduce long-term healthcare costs. The region hosts several leading pharmaceutical and medical device companies that are actively investing in smart and connected delivery platforms. Companies such as Propeller Health, Medtronic, Adherium, and Becton Dickinson are either headquartered in or have a substantial market focus on North America. Their continuous product development, strategic partnerships, and pilot programs across health systems have fueled rapid technology deployment and market penetration.

Recent Developments

• In April 2025, Medtronic plc announced that the U.S. Food and Drug Administration (FDA) has approved its Simplera Sync™ sensor for use with the MiniMed™ 780G insulin delivery system. This approval enhances the flexibility of Medtronic’s most advanced insulin management platform, which now supports both the Guardian™ 4 sensor and the new Simplera Sync™ sensor. The MiniMed™ 780G system, which features Meal Detection™ technology, offers automated insulin delivery tailored to real-time glucose levels, enabling improved personalization and convenience for diabetes patients.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S
• Phillips Medisize
• Medtronic Plc.
• Adherium Limited
• Tandem Diabetes Care, Inc.
• Biocorp Life Sciences Pvt. Ltd
• Resmed Corp
• Ypsomed AG
• AptarGroup, Inc

Report Scope:

In this report, the Global Connected Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Connected Drug Delivery Devices Market, By Product Type:

o   Standalone Components & Software

o   Integrated Devices

• Connected Drug Delivery Devices Market, By Route of Administration:

o   Parenteral

o   Inhalational

• Connected Drug Delivery Devices Market, By Application:

o   Asthma

o   COPD

o   Diabetes Management

o   Others

• Connected Drug Delivery Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Connected Drug Delivery Devices Market.

Available Customizations:

Global Connected Drug Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).